Soterix Begins RECOVER-NEURO Trial for Long COVID

Soterix Medical has begun a Phase-2 clinical trial to evaluate combining its REMOTE-tDCS and a brain training program to treat long COVID. The trial will be administered through NYU Langone Health’s home-based, remotely supervised (RS) tDCS program, which includes a clinical service available to U.S. patients.
 
The Researching COVID to Enhance Recovery (RECOVER) Initiative was made to address long COVID’s widespread and diverse impacts. The RECOVER-NEURO study will assess interventions for cognitive dysfunction related to long COVID, including brain fog, memory problems and difficulty with attention, thinking clearly, and problem solving.
 
Interventions include Posit Science’s digital cognitive training program PASC-Cognitive Recovery, which is a web-based, goal management training program built by Mount Sinai Health System and Soterix’s home-based transcranial direct current stimulation (tDCS) system for use in RS-tDCS.
 
RECOVER-NEURO aims to test up to 315 participants.
 
Dr. Abhishek Datta, CEO of Soterix Medical told the press, “The Soterix Medical REMOTE-tDCS platform is the most validated hardware and software system for home-based tDCS. REMOTE-tDCS combines unique accessories, tDCS-LTE hardware, and telemedicine which can be customized for each clinical indication. NIH RECOVER-NEURO develops a Long COVID treatment based on digital therapy and Soterix Medical’s REMOTE-tDCS platform.”
 
“It’s a great advance to see incorporation of tDCS treatment arms in the RECOVER initiative,” added Dr. Leigh Charvet, Ph.D., professor in the Department of Neurology and director of the tDCS program at NYU Langone. “This trial was informed by previous findings that the combination of tDCS and online cognitive training can assist in recovery from long COVID, including improved cognitive function.” 
 
Kamran Nazim, chief product officer of Soterix said, “Soterix Medical tDCS-LTE platforms have been shown in prior studies to improve cognition in healthy adults, and have shown promise in a variety of clinical conditions, including many conditions associated with cognitive or attention impairment or brain fog. Basic science studies have shown a dual action of tDCS-LTE deriving from both boosting brain plasticity and enhancing brain blood flow. This provides a strong rationale for testing tDCS-LTE for Long COVID.”